ASCO Virtual Meeting, 29 May–2 June 2020

A Phase I, open-label, dose escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors

Eelke Gort, Melissa Johnson, Jimmy Hwang, Shubham Pant, Ulrich Dünzinger, Kathrin Riemann, Thomas Kitzing, Pasi Jänne

ASCO 2020_Poster #381_Gort_SOS KRAS 1432.1 TiP

References

sos_kras_1432.1_tip_asco_landing_page_130520.png

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

FOR HEALTHCARE PROFESSIONAL ONLY

links_to_3rd_party.jpg